Tweets
UTSW Rheum Grand Rounds
MAS occurs in 2-8% of Systemic JIA pts and has a high mortality (<40%); It is more frequent w/ onset in Years 1-4. Treatment - steroids, anakinra, etoposide or CsA & Rx infxn if present. Oh...dont stop the anakinra! @UTSWRheum https://t.co/09uQm3LURC
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
UTSW Rheum Grand Rounds
IL-18 levels are elevated in systemic JIA, MAS and AOSD @UTSWRheum https://t.co/pIYKf4pods
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
Dr. Peter Nigrovic asserts the division between pediatric and adult arthritis is senseless and has no firm biologic basis. Instead we should consider pts as sero- positive or negative, Systemci or Spondyloarthropathy. @UTSWRheum https://t.co/zx5oQmUQ6Y
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
van Vollenhoven et al strategies onT2T in SLE
1) Choose a Target; treat, monitor, adjust
2) LLDAS & DORIS remission are good targets
3) T2T trials needed w/ current Rx & new biologics & sm molecules
4) LLDAS & DORIS as outcomes in clinical trials
https://t.co/aTq398iaSD https://t.co/yWlp4vY7kh
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
UTSW Rheum Grand Rounds with Dr. Peter Nigrovic on systemic JIA in children and adults; yes, its the same disease with the same features. @UTSWRheum https://t.co/C7eBFjnDIi
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
Network metanalysis (28 RCTs, 12 504 pts) of Biologics & small molecules therapy in active ulcerative colitis. Upadacitinib 45 mg qd ranked 1st (RR 0.73) vs PBO, infliximab 5 mg/kg & 10 mg/kg ranked 2nd & 3rd. UPA > TNFi at remission. https://t.co/PPNkfXiJSL
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
UCB announced top-line interim analysis results from their Phase 3 "BE MOBILE 1" study, that demonstrated the efficacy of bimekizumab, a dual IL-17A and F inhibitor, in adults with active non-radiographic axial spondyloarthritis (nr-axSpA).
https://t.co/FylgQ30Dva https://t.co/XJ4y0U60hu
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
How Bad and How Far? CDC says to date, in the USA, there have been 6,715,937 COVID cases and 850,575 deaths from COVID-19. A total of 249,393,487 (75.1%) have recv at least one VAX dose, 209,312,770 (63%) fully VAX, 38.7% had a booster dose https://t.co/M9fYWL80ae
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
Using SKG mouse model of adjuvant induced SpA and enthesitis, neutrophils, and inducible IL-23, were shown to play an important role in early murine spondyloarthritis-related enthesitis. https://t.co/wlHXkNbvR7
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
192 early arthritis & 693 early arthralgia underwent the MTP-squeeze-test (MTPsqT) & MRI. Synovitis & intermetatarsal bursitis (IMB) were assoc w/ MTPsqT. In EA, MTPsqT +, 79% had synovitis or IMB: 12% synovitis, 15% IMB & 52% had both. https://t.co/Ojwb8KkmLu
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
ASK CUSH ANYTHING!
Have a Rheumatology question or case for Dr. Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/LAC6XrYEyN https://t.co/POGHk7Ibq2
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
FDA has approved 2 JAK inhibitors for use in severe atopic dermatitis (eczema) - Abbvies upadacitinib (Rinvoq) and Pfizers abrocitinib (Cibinqo). https://t.co/WpCehmB7Vz https://t.co/qKoqV08Z86
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
